Abstract
Competition arising from the increasing availability of biosimilar medicines has resulted in healthcare savings and has provided greater patient access to high cost therapeutics in Europe. The biosimilar market in the USA is relatively new so the full impact of biosimilar availability remains to be seen. Educational initiatives relating to the use of biosimilar medicines are currently being undertaken by regulators, policy makers and industry. The debate on biosimilars has moved on from the appropriateness of the regulatory framework which governs their approval, to the practice of interchangeability. Interchangeability is an important issue for healthcare professionals but different definitions and regulatory frameworks exist in the USA and Europe. In the USA, an interchangeable biological product is a biosimilar which may be substituted by a pharmacist, subject to local State policies. The interchangeability of a biosimilar with its reference medicine will be evaluated by the United States Food and Drug Administration (FDA) in cases where approval as an ‘interchangeable product’ is sought. In contrast, the European Medicines Agency (EMA) does not assess or make recommendations on interchangeability, therefore, in Europe, interchangeability does not mean substitution but is generally physician-led or driven by national policy. This paper provides an overview of the regulation of biosimilar medicines. Challenges associated with the demonstration of interchangeability and practical considerations relating to switching are also discussed. Finally, we present policies that have been adopted to date in several European countries, the USA and Australia, which aim to promote the use of biosimilar medicines.
Similar content being viewed by others
References
Cornes P (2012) The economic pressures for biosimilar drug use in cancer medicine. Target Oncol 7(Suppl 1):S57–S67
McCamish M, Woollett G (2011) Worldwide experience with biosimilar development. MAbs 3(2):209–217
IMS Health (2017) The impact of biosimilar competition in Europe. Available from: http://ec.europa.eu/DocsRoom/documents/23102. 5 Aug 2018
Food and Drug Administration (FDA) (2015) FDA approves first biosimilar product Zarxio. Available from: https://wayback.archive-it.org/7993/20170111224313/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. 5 Aug 2018
Walsh G, Jefferis R (2006) Post-translational modifications in the context of therapeutic proteins. Nat Biotech 24(10):1241–1252
Schellekens H (2009) Assessing the bioequivalence of biosimilars. The Retacrit case. Drug Discov Today 14(9–10):495–499
Food and Drug Administration (FDA) (2015) Scientific considerations in demonstrating biosimilarity to a reference product, guidance for industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291128.pdf. 5 Aug 2018
European Medicines Agency (EMA) (2014) Guideline on similar biological medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. 5 Aug 2018
Food and Drug Administration (FDA) (2015) Quality considerations in demonstrating biosimilarity of a therapeutic protein product to a reference product, guidance for industry. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm291134.pdf. 5 Aug 2018
Bui LA et al (2015) Key considerations in the preclinical development of biosimilars. Drug Discov Today 20(Suppl 1):3
van Aerts LA et al (2014) Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union. MAbs 6(5):1155–1162
European Medicines Agency (EMA) (2015) Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non clinical and clinical issues. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2015/01/WC500180219.pdf. 5 Aug 2018
Weise M et al (2012) Biosimilars: what clinicians should know. Blood 120(26):5111–5117
Li EC et al (2015) Considerations in the early development of biosimilar products. Drug Discov Today 20(Suppl 2):1–9
Weise M et al (2014) Biosimilars: the science of extrapolation. Blood 124(22):3191–3196
Cohen H et al (2016) Awareness, Knowledge, and Perceptions of Biosimilars Among Specialty Physicians. Adv Ther 33(12):2160–2172
Grabowski D et al (2015) Attitudes towards subsequent entry biologics/biosimilars: A survey of Canadian rheumatologists. Clin Rheumatol 34(8):1427–1433
O'Callaghan J et al (2017) Assessing awareness and attitudes of healthcare professionals on the use of biosimilar medicines: A survey of physicians and pharmacists in Ireland. Regul Toxicol Pharmacol 88:252–261
Beck M et al (2016) Rheumatologists’ Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey. Memo 30(6):585–592
Günther Gastl MD et al (2009) ASHO position paper on Biosimilars. Memo 2(4):232–233
Fiorino G et al (2014) The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper. Autoimmun Rev 13(7):751–755
Argüelles-Arias F et al (2013) Joint position statement by “Sociedad Española de Patología Digestiva” (Spanish Society of Gastroenterology) and “Sociedad Española de Farmacología” (Spanish Society of Pharmacology) on biosimilar therapy for inflammatory bowel disease. Rev Esp Enferm Dig 105(1):37–43
International Conference for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) (2004) Comparability of biotechnological/biological products subject to changes in their manufacturing process Q5E. Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Quality/Q5E/Step4/Q5E_Guideline.pdf. 5 Aug 2018
Schneider CK (2013) Biosimilars in rheumatology: the wind of change. Ann Rheum Dis 72:315–8
Declerck P, Farouk-Rezk M, Rudd PM (2016) Biosimilarity Versus Manufacturing Change: Two Distinct Concepts. Pharm Res 33(2):261–268
Ramanan S, Grampp G (2014) Drift, evolution, and divergence in biologics and biosimilars manufacturing. GaBI J 28(4):363–372
Gerrard TL, Johnston G and Gaugh DR (2015) Biosimilars: extrapolation of clinical use to other indications. GaBI J 4(3):118–24
European Medicines Agency (EMA) (2016) Guideline on good pharmacovigilance practices (GVP). Product- or population-specific considerations II: biological medicinal products. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/08/WC500211728.pdf. 5 Aug 2018
Schellekens H (2002) Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 24(11):1720–1740 discussion 1719
Schellekens H (2005) Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol 18(3):473–480
European Parliament and the Council of the European Union (2012) Directive 2001/83/EC of the European Parliament and of the Council of November 2001 on the Community Code Relating to Medicinal Products for Human Use (Consolidated version). Brussels, Belgium
Scavone C et al (2017) Strengths, weaknesses and future challenges of biosimilars’ development. An opinion on how to improve the knowledge and use of biosimilars in clinical practice. Pharmacol Res 126:138–142
Inotai A et al (2017) Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars. Expert Opin Biol Ther 17(8):915–926
Dranitsaris G, Amir E, Dorward K (2011) Biosimilars of Biological Drug Therapies: Regulatory, Clinical and Commercial Considerations. Drugs 71(12):1527–1536
European Medicines Agency (EMA) and European Commission (EC) (2017) Biosimilars in the EU: Information guide for healthcare professionals. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. 5 Aug 2018
Cauchi R (2018) State laws and legislation related to biologics medications and substitution of biosimilars. Available from: http://www.ncsl.org/research/health/state-laws-and-legislation-related-to-biologic-medications-and-substitution-of-biosimilars.aspx. 5 Aug 2018
Food and Drug Administration (FDA) (2017) Considerations in demonstrating interchangeability with a reference product, draft guidance for industry. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM537135.pdf. 5 Aug 2018
American College of Rheumatology (ACR) (2016) Position statement on Biosimilars. Available from: http://www.rheumatology.org/Portals/0/Files/Biosimilars-Position-Statement.pdf. 5 Aug 2018
Faccin F et al (2016) The design of clinical trials to support the switching and alternation of biosimilars. Expert Opin Biol Ther 16(12):1445–1453
Dorner T, Kay J (2015) Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol 11(12):713–724
Trifiro G, Marciano I, Ingrasciotta Y (2018) Interchangeability of biosimilar and biological reference product: updated regulatory positions and pre- and post-marketing evidence. Expert Opin Biol Ther 18(3):309–315
Kurki P et al (2017) Interchangeability of biosimilars: a European perspective. BioDrugs 31(2):83–91
Braun J, Kudrin A (2016) Switching to biosimilar infliximab (CT-P13): evidence of clinical safety, effectiveness and impact on public health. Biologicals 44(4):257–266
McKinnon RA et al (2018) Biosimilarity and interchangeability: principles and evidence: a systematic review. BioDrugs 32(1):27–52
Cohen HP et al (2018) Switching reference medicines to biosimilars: a systematic literature review of clinical outcomes. Drugs 78(4):463–478
Ebbers HC, Muenzberg M, Schellekens H (2012) The safety of switching between therapeutic proteins. Expert Opin Biol Ther 12(11):1473–1485
European Medicines Agency (EMA) (2018) EMA Public Assessment Reports Website. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. 5 Aug 2018
Food and Drug Administration (FDA) (2016) FDA News Release: FDA approves Inflectra, a biosimilar to Remicade. Available from: https://www.fda.gov/newsevents/newsroom/pressannouncements/ucm494227.htm. 5 Aug 2018
European Medicines Agency (EMA) (2013) Press release: European Medicines Agency recommends approval of first two monoclonal antibody biosimilars. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2013/06/WC500144941.pdf
Yoo DH et al (2017) Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis 76(2):355
Park W et al (2017) Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis 76(2):346
Jorgensen KK et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet 389(10086):2304–2316
Blackwell K et al (2018) Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol 29(1):244–249
Griffiths CEM et al (2017) The EGALITY study: a confirmatory, randomized, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, vs. the originator product in patients with moderate-to-severe chronic plaque-type psoriasis. Br J Dermatol 176(4):928–938
Blauvelt A et al (2018) Phase III randomized study of the proposed adalimumab biosimilar GP2017 in psoriasis: impact of multiple switches. Br J Dermatol. https://doi.org/10.1111/bjd.16890
Ebbers HC, Chamberlain P (2014) Interchangeability. An insurmontable fifth hurdle? GaBI J 3(2):88–93
D’Haens GR et al (2011) The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 106(2):199–212 quiz 213
Ormerod AD (2010) Switching biologics for psoriasis. Br J Dermatol 163(4):667–669
Valensi P et al (2009) Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. Int J Clin Pract 63(3):522–531
Smolen JS et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977
Thimmaraju PK et al (2015) Legislation on biosimilar interchangeability in the US and EU - developments far from visibility. Generics and Biosimilars Initiative Online (GaBI) Available from: http://www.gabionline.net/Sponsored-Articles/Legislations-on-biosimilar-interchangeability-in-the-US-and-EU-developments-far-from-visibility. 5 Aug 2018
Rezk MF, Pieper B (2017) Treatment outcomes with biosimilars: be aware of the nocebo effect. Rheumatol Ther 4(2):209–218
Faasse K, Petrie KJ (2013) The nocebo effect: patient expectations and medication side effects. Postgrad Med J 89(1055):540–546
Boone NW et al (2018) The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol 74(5):655–661
Tweehuysen L et al (2018) Subjective complaints as the main reason for biosimilar discontinuation after open-label transition from reference infliximab to biosimilar infliximab. Arthritis Rheumatol 70(1):60–68
Nikiphorou E et al (2015) Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther 15(12):1677–1683
Glintborg B et al (2017) A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry. Ann Rheum Dis 76(8):1426–1431
Underhill C (2016) Biosimilars and IBD: a switch programme using CT-P13. Clin Pharm 8(9):266–270
Health Products Regulatory Authority (HPRA) (2017) Biological and biosimilar medicines: what patients should know. Available from: http://www.hpra.ie/homepage/medicines/special-topics/biosimilar-medicines/questions-and-answers-for-patients. 5 Aug 2018
European Commission (EC) (2017) What I need to know about biosimilar medicines, information for patients. Available from: http://ec.europa.eu/docsroom/documents/26643. 5 Aug 2018
British Oncology Pharmacy Association (BOPA) (2017) Guidelines on implementation of biosimilar monoclonal antibodies. Available from: http://www.bopawebsite.org/sites/default/files/publications/Biosimilar%20MABs%20Implimentation%20Guidelines%20%26%20BOPA%20Position%20Statement%2005.02.17.pdf. 5 Aug 2018
Mack A (2015) Norway, biosimilars in different funding system. What works? GaBI J 4(2):90–92
Lunddahl B (2016) Pharmacovigilance on biologicals and biosimilars: a Danish perspective. GaBI J 5(3):123–124
Remuzat C et al (2017) Supply-side and demand-side policies for biosimilars: an overview in 10 European member states. J Mark Access Health Policy 5(1):1307315
Renwick MJ et al (2016) Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol 17(1):e31–e38
Lepage-Nefkens I et al (2013) Barriers and opportunities for the uptake of biosimilar medicines in Belgium. Available from: https://kce.fgov.be/sites/default/files/atoms/files/KCE_199_2012-13-HSR_Biosimilars_report_0.pdf. 5 Aug 2018
Remuzat C et al (2017) Key drivers for market penetration of biosimilars in Europe. J Mark Access Health Policy 5(1):1272308
Flume M (2016) Regional management of biosimilars in Germany. GaBI J 5(3):125–127
Flodmark C-E et al (2013) Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden. Biol Ther 3(1):35–43
Danese S et al (2017) ECCO position statement on the use of biosimilars for inflammatory bowel disease-an update. J Crohns Colitis 11(1):26–34
British Society of Gastroenterology (BSG) (2016) BSG guidance on the use of biosimilar infliximab CT-P13 in IBD. Available from: https://www.bsg.org.uk/resource/bsg-guidance-on-the-use-of-biosimilar-infliximab-ct-p13-in-ibd.html. 5 Aug 2018
Pharmaceutical Society of Australia (PSA) (2015) Biosimilar medicines: position statement. Available from: http://www.psa.org.au/downloads/ent/uploads/filebase/policies/biosimilar-medicines-position-statement.pdf. 5 Aug 2018
Danish Medicines Agency (2016) Danish Pharmacovigilance Update, No. 10, Volume 7, November 2016. Available from: https://laegemiddelstyrelsen.dk/en/news/danish-pharmacovigilance-update,-archive/danish-pharmacovigilance-update,-november-2016/~/media/247B0EAC7C464D508461F3B6795A5473.ashx. 5 Aug 2018
Australian Government Department of Health (2018) Biosimilar awareness initiative website. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-awareness-initiative. 5 Aug 2018
Australian Government Department of Health (2018) Pharmaceutical Benefits Advisory Committee (PBAC) membership. Available from: https://www.pbs.gov.au/info/industry/listing/participants/pbac. 5 Aug 2018
Australian Government Department of Health (2018) The pharmaceutical benefits scheme: symbols used in the schedule. Available from: http://www.pbs.gov.au/info/healthpro/explanatory-notes/section2/section-2-symbols. 5 Aug 2018
Australian Government Department of Health (2017) Who chooses whether the biosimilar medicine or the reference biological medicine is used? Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/biosimilar-who-chooses-whether-biosimilar-medicine-or-reference-biological-medicine-is-used. 5 Aug 2018
Feely J et al (1997) Low rate of generic prescribing in the Republic of Ireland compared to England and Northern Ireland: prescribers’ concerns. Ir Med J 90(4):146–147
O’Leary A et al (2015) Generic medicines and generic substitution: contrasting perspectives of stakeholders in Ireland. BMC Res Notes 8(1):790
Dunne SS et al (2014) Beliefs, perceptions and behaviours of GPs towards generic medicines. Fam Pract 31(4):467–474
Murphy M (1997) Review of indicative drug target saving scheme. Available from: https://www.lenus.ie/hse/bitstream/10147/45486/1/8025.pdf. 5 Aug 2018
Christl LA, Woodcock J, Kozlowski S (2017) Biosimilars: the US regulatory framework. Annu Rev Med 14(68):243–254
Food and Drug Administration (FDA) (2018) Biosimilars. Available from: https://www.fda.gov/drugs/developmentapprovalprocess/howdrugsaredevelopedandapproved/approvalapplications/therapeuticbiologicapplications/biosimilars/default.htm. 5 Aug 2018
Annese V et al (2016) Roundtable discussion on biosimilars with European regulators and medical societies, Brussels, Belgium 12 January 2016. GaBI J 5(2):74–83
Acknowledgments
This work was supported by the Health Products Regulatory Authority (HPRA), Regulatory Science Ireland and University College Cork. Brendan T. Griffin is also supported in part by the Irish Pharmaceutical Healthcare Association (IPHA) in the form of a research grant to support regulatory science research.
The authors wish to thank the following for advice with this study: Una Moore (HPRA), Sandra Bright (HPRA) and Maeve Lally (HPRA).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Joan O’Callaghan, Sean P. Barry, Brendan T. Griffin, J. Michael Morris and Margaret Bermingham declare that they have no conflict of interest. This paper represents solely the views of the authors and should not be understood or quoted as being made on behalf of or reflecting the position of the Health Products Regulatory Authority or Regulatory Science Ireland.
Electronic supplementary material
ESM 1
(DOCX 24 kb)
Rights and permissions
About this article
Cite this article
O’Callaghan, J., Barry, S.P., Bermingham, M. et al. Regulation of biosimilar medicines and current perspectives on interchangeability and policy. Eur J Clin Pharmacol 75, 1–11 (2019). https://doi.org/10.1007/s00228-018-2542-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00228-018-2542-1